(Source: Delcath Systems Inc) DELCATH ANNOUNCES ODAC MEETING REVIEW DATE FOR ITS PROPRIETARY DRUG/DEVICE COMBINATION PRODUCT DELCATH HEPATIC DELIVERY SYSTEM Meeting to be Held May 2, 2013 NEW YORK, Feb. 27, 2013 -- Delcath Systems, Inc. (NASDAQ: DCTH) today announced that the U.S. Food and Drug Administration's (FDA) Oncologic Drugs Advisory Committee (ODAC) will review the Company's pending New Drug Application (NDA) for a drug/device combination product with the proposed trade name Melblez KitTM (Melblez (melphalan) for Injection for use with the Delcath Hepatic Delivery System. The ODAC meeting will be convened Thursday, May 2, 2013, to review the NDA with a proposed indication...
0 Responses to DELCATH ANNOUNCES ODAC MEETING REVIEW DATE FOR ITS PROPRIETARY DRUG/DEVICE COMBINATION PRODUCT DELCATH HEPATIC DELIVERY SYSTEM (Delcath Systems Inc)